Company Profile

Biocorp specializes in the development and manufacture of medical devices and drug delivery systems. The company offers traditional delivery systems, connected injection systems and monitoring devices. Net sales break down by source of income between sales of services (86.9%) and products (13.1%). At the end of 2022, Biocorp has a production site located in France. France accounts for 62.6% of net sales.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

23-10-02	Biocorp: Novo Nordisk exceeds 90% of share capital
23-09-29	Biocorp: Novo Nordisk holds 97.8% of the capital
23-09-07	Biocorp: simplified tender offer opened on September 7
23-09-06	Biocorp: AMF gives go-ahead to proposed simplified tender offer
23-09-04	Biocorp Production Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-08-07	CAC40: anecdotal rise, caution prevails
23-08-07	CAC40: hovering around 7300 pts, low volumes
23-08-07	CAC40: regains some color and crosses 7300 pts
23-08-07	CAC40: Caution prevails as the week begins with a slight decline
23-08-07	Biocorp: takeover by Novo Nordisk completed
23-08-06	Denmark's Novo Nordisk Closes Biocorp's Controlling Stake Deal	MT
23-08-03	Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of a 64.4% stake in Biocorp Production from Vatel Capital SAS, Nyenburgh Investment Partners, BIO JAG and Greenstock	CI
23-06-19	Global markets live: Airbus, Intel, Meta Platforms, Berkshire Hathaway...

23-08-28	Biocorp : Franchissement de seuil	PU
22-12-07	BIOCORP Obtains 510(k) FDA Clearance for Mallya	AQ
21-09-20	Biocorp : Upcoming investor meetings	PU
21-09-16	BIOCORP : and MERCK KGaA sign a partnership in the field of Human Growth Hormone	PU
21-04-13	BIOCORP : and ROCHE DIABETES CARE FRANCE launch Mallya in France	PU

24-11-20	PLFSS 2025: le gouvernement veut actionner la clause de sauvegarde sur les dispositifs médicaux
23-11-08	Medtech: les industriels demandent une "réforme globale" de la réglementation européenne
23-10-02	Biocorp : Communiqués publiés en période d'offre publique d'acquisition / OPA Autres communiqués
23-10-02	Biocorp : Novo Nordisk dépasse les 90% du capital
23-09-29	Biocorp : Novo Nordisk détient 97,8% du capital

Manager	Title	Age	Since
Stéphane Chabanais DFI	Director of Finance/CFO	-	-
Sylvaine Dessard SAM	Sales & Marketing	-	-
Arnaud Guillet PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Emilie Gardette BRD	Director/Board Member	-	2015-05-11
Julien Gardette BRD	Director/Board Member	-	2015-05-11
Jean-Yves Berthon BRD	Director/Board Member	-	2015-05-11

Biocorp Stock

Stocks

ALCOR

FR0012788065

Advanced Medical Equipment & Technology

Latest news: Biocorp

Press Releases: Biocorp

News in other languages: Biocorp

Managers and Directors: Biocorp

Latest insider transactions

Other Advanced Medical Equipment & Technology

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/20/23	Eric Dessertenne	Buy	Chief Executive Officer	6,000	0.1360%
9/20/23	Eric Dessertenne	Buy	Chief Executive Officer	7,450	0.1688%
9/19/23	Eric Dessertenne	Buy	Chief Executive Officer	30,000	0.6799%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCORP	-.--%	-.--%	-	-	173M
THERMO FISHER SCIENTIFIC, INC.	+2.30%	+1.96%	+23.08%	+56.03%	253B
DANAHER CORPORATION	+0.94%	-1.23%	+6.84%	+19.24%	160B
INTUITIVE SURGICAL, INC.	+0.89%	-2.41%	-17.51%	+58.61%	151B
BOSTON SCIENTIFIC CORPORATION	-1.85%	-4.56%	-56.81%	-17.17%	64.23B
SIEMENS HEALTHINEERS AG	-0.12%	+2.51%	-10.75%	-8.53%	54.11B
EDWARDS LIFESCIENCES CORPORATION	+2.07%	+5.11%	+15.45%	+45.26%	53.76B
VEEVA SYSTEMS INC.	-1.23%	-4.70%	+4.12%	+59.66%	49.71B
AGILENT TECHNOLOGIES, INC.	+2.02%	-0.28%	+19.88%	+67.95%	48.49B
WATERS CORPORATION	+2.31%	+0.86%	+31.55%	+87.40%	44.17B
Average	+0.60%	-0.76%	+1.76%	+40.94%	97.69B
Weighted average by Cap.	+0.91%	-0.75%	+3.92%	+42.22%